Document is current
Any future updates will be listed below
-
Authors
Zajicek, Franziska https://orcid.org/0000-0001-5410-687X
Everix, Liesbeth https://orcid.org/0000-0001-5985-1609
Van Eetveldt, Annemie https://orcid.org/0000-0002-6488-5456
Verhaeghe, Jeroen https://orcid.org/0000-0002-4493-1902
De Lombaerde, Stef https://orcid.org/0000-0002-5307-3575
Miranda, Alan https://orcid.org/0000-0002-5381-015X
Akkermans, Jordy https://orcid.org/0000-0002-1533-9504
Dominguez, Celia
Khetarpal, Vinod https://orcid.org/0000-0002-2175-5117
Bard, Jonathan https://orcid.org/0000-0002-5097-1361
Liu, Longbin https://orcid.org/0000-0003-3995-0196
Staelens, Steven https://orcid.org/0000-0003-3376-0519
Bertoglio, Daniele https://orcid.org/0000-0003-4205-5432
-
Funding
Funding for this research was provided by:
CHDI Foundation (A-11627)
Fonds Wetenschappelijk Onderzoek (1229721N)
- License Information
-
More Information
Article History
Received: 4 June 2025
Revised: 1 October 2025
Accepted: 29 October 2025
First Online: 18 December 2025
Declarations
:
: Experiments followed the European Committee (decree 2010/63/CEE) and were approved by the Ethical Committee for Animal Testing (ECD 2019–39) at the University of Antwerp (Belgium).
: This work was funded by CHDI Foundation, Inc., a privately-funded nonprofit biomedical research organization exclusively dedicated to collaboratively developing therapeutics that improve the lives of those affected by Huntington’s disease. CD, VK, JB, and LL are employed by CHDI Management, Inc., the company that manages the scientific activities of CHDI Foundation. No other potential conflicts of interest relevant to this article exist.
